Investments 

Rotating away from larger biotech names could be way forward

Rotating away from larger biotech names could be way forward

After a disappointing performance in the first half of 2018, healthcare stocks headed north in the third quarter and the Nasdaq Biotechnology index gained 11.2 per cent. 

The content you are trying to access is only available to users with an FTAdviser.com subscription

Subscribe to FTAdviser now for:

- Full access to articles written by the Money Management team

- No limit to the number of articles you can read every month

- The ability to use Money Management's uniquely prepared fund statistics - on the web, or by downloading a pdf

Unlock unlimited articles
Subscribe

Comments